IL-5 release of CD4+ non-effector lymphocytes is increased in COPD - Modulating effects of moxifloxacin and dexamethasone

International Immunopharmacology

Volumn 11, Issue 4, 2011, Pages 444-448

  Schild, Katharina ^a   Knobloch, Jürgen ^a   Yakin, Yakup ^a   Jungck, David ^a   Urban, Katja ^a   Müller, Katja ^a   Koch, Andrea ^a,b  

^a UNIVERSITY OF COLOGNE   (Germany)

^b RUHR UNIVERSITY BOCHUM   (Germany)

Author keywords

COPD; IL 5; Lipopolysaccharide (LPS); Lymphocyte; Moxifloxacin

Indexed keywords

BACTERIUM LIPOPOLYSACCHARIDE; DEXAMETHASONE; ENDOTOXIN; INTERLEUKIN 5; MOXIFLOXACIN;

ADULT; ARTICLE; CD4+ T LYMPHOCYTE; CELL ISOLATION; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOKINE RELEASE; DISEASE EXACERBATION; DRUG MECHANISM; EX VIVO STUDY; FEMALE; GRAM NEGATIVE INFECTION; HUMAN; HUMAN CELL; IMMUNE DEFICIENCY; IMMUNOMODULATION; LYMPHOCYTE DIFFERENTIATION; MALE; PRIORITY JOURNAL; RESPIRATORY AIRFLOW; SMOKING; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME; T LYMPHOCYTE ACTIVATION; TH2 CELL;

AZA COMPOUNDS; CASE-CONTROL STUDIES; CD4-POSITIVE T-LYMPHOCYTES; DEXAMETHASONE; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; IMMUNOLOGIC FACTORS; INTERLEUKIN-5; MALE; MIDDLE AGED; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; QUINOLINES; SMOKING; TH2 CELLS;

EID: 79952738955     PISSN: 15675769     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.intimp.2010.12.013     Document Type: Article

References (28)

1. Lopez AD, Shibuya K, Rao C, Mathers CD, Hansell AL, Held LS, et al. Chronic obstructive pulmonary disease: current burden and future projections. Eur Respir J 2006;27(2):397-412. (Pubitemid 43180921)
2. Cornwell WD, Kim V, Song C, Rogers TJ. Pathogenesis of inflammation and repair in advanced COPD. Semin Respir Crit Care Med 2010;31(3):257-66.
3. Fabbri LM, Luppi F, Beghé B, Rabe KF. Complex chronic comorbidities of COPD. Eur Respir J 2008;31(1):204-12.
4. Magnussen H, Watz H. Systemic inflammation in chronic obstructive pulmonary disease and asthma: relation with comorbidities. Proc Am Thorac Soc 2009;6(8): 648-51.
5. Wedzicha JA, Seemungal TAR. COPD exacerbations: defining their cause and prevention. Lancet 2007;370(6589):786-96. (Pubitemid 47320802)
6. Cosio MG, Saetta M, Agusti A. Immunologic aspects of chronic obstructive pulmonary disease. NEJM 2009;360(23):2445-54.
7. Barnes PJ. The cytokine network in chronic obstructive pulmonary disease. Am J Respir Cell Mol Biol 2009;41(6):631-8.
8. Makris D, Lazarou S, Alexandrakis M, Kourelis TV, Tzanakis N, Kyriakou D, et al. Tc2 response at the onset of COPD exacerbations. Chest 2008;134(3):483-8.
9. Lu YC, Yeh WC, Ohashi PS. LPS/TLR4 signal transduction pathway. Cytokine 2008;42(2):145-51.
10. Knobloch J, Schild K, Jungck D, Urban K, Müller K, Schweda EK, Rupp J, Koch A. The T-Helper Cell Type 1-Immune Response to Gram-Negative Bacterial Infections is Impaired in COPD. Am J Respir Crit Care Med in press, doi:10.1164/rccm.201002-0199OC.
11. Barnes PJ, Adcock IM. Glucocorticoid resistance in in inflammatory diseases. Lancet 2009;373(9678):1905-17.
12. Barnes PJ. Alveolar macrophages in chronic obstructive pulmonary disease (COPD). Cell Mol Biol (Noisy-le-grand) 2004;50 [Online Pub:OL627-37].
13. Knobloch J, Sibbing B, Jungck D, Lin Y, Urban K, Stoelben E, Strauch J, Koch A. Resveratrol impairs the release of steroid-resistant inflammatory cytokines from human airway smooth muscle cells in COPD. J Pharmacol Exp Ther 2010;335: 778-98.
14. Miravitlles M. Moxifloxacin in the management of exacerbations of chronic bronchitis and COPD. Int J Chron Obstruct Pulmon Dis 2007;2(3):191-204. (Pubitemid 350110894)
15. Williams AC, Galley HF, Watt AM, Webster NR. Differential effects of three antibiotics on t helper cell cytokine expression. J Antimicrob Chemother 2005;56 (3):502-6. (Pubitemid 41264127)
16. Rabe KF, Hurd S, Anzueto A, Barnes PJ, Buist SA, Calverley P, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. GOLD Executive Summary. Am J Respir Crit Care Med 2007;176(6): 532-55. (Pubitemid 47403272)
17. Koch A, Knobloch J, Dammhayn C, Raidl M, Ruppert A, Hag H, et al. Effect of bacterial endotoxin LPS on expression of IFNγ and IL-5 in T-lymphocytes from asthmatics. Clin Immunol 2007;125(2):194-204. (Pubitemid 47562901)
18. Burkhardt O, Welte T. 10 years' experience with the pneumococcal quinolone moxi.oxacin. Expert Rev Anti Infect Ther 2009;7(6):645-68.
19. Barceló B, Pons J, Fuster A, Sauleda J, Noguera A, Ferrer JM, et al. Intracellular cytokine profile in patients with chronic obstructive pulmonary disease. Clin Exp Immunol 2006;145(3):474-9. (Pubitemid 44252490)
20. Panzner P, Lafitte JJ, Tsicopoulos A, Hamid Q, Tulic MK. Marked up-regulation of T lymphocytes and expression of interleukin-9 in bronchial biopsies from patients with chronic bronchitis with obstruction. Chest 2003;124(5):1909-15. (Pubitemid 37433591)
21. Lambers C, Hacker S, Posch M, Hoetzenecker K, Pollreisz A, Lichtenauer M, et al. T cell senescence and contraction of T cell repertoire diversity in patients with chronic obstructive pulmonary disease. Clin Exp Immunol 2009;155(3):466-75.
22. Majori M, Corradi M, Carminati A, Cacciani G, Bertacco S, Pesci A. Predominant TH1 cytokine pattern in peripheral blood from subjects with chronic obstructive pulmonary disease. J Allergy Clin Immunol 1999;103(3 Pt 1):458-62. (Pubitemid 29136299)
23. Hansel TT, Barnes PJ. New drugs for exacerbations of chronic obstructive pulmonary disease. Lancet 2009;374(9691):744-55.
24. Papi A, Luppi F, Franco F, Fabbri LM. Pathophysiology of exacerbations of chronic obstructive pulmonary disease. Proc Am Thorac Soc 2006;3(3):245-51. (Pubitemid 43668189)
25. Kharitonov SA, Sjoebring U. Lipopolysaccharide challenge of human as a model of chronic obstructive lung disease exacerbations. Contrib Microbiol 2007;14: 83-100.
26. Van Bambeke F, Tulkens PM. Safety profile of the respiratory fluorchinolone moxifloxacin comparison with other fluorchinolones and other antibacterial classes. Drug Saf 2009;32(5):359-78.
27. Zimmermann GS, Neurohr C, Villena-Hermoza H, Hatz R, Behr J. Anti-inflammatory effects of antibacterials on human bronchial epithelial cells. Respir Res 2009;10(1):89.
28. Moore WC, Pascual RM. Update in asthma 2009. Am J Respir Crit Care Med 2010;181(11):1181-7.